Super-TDU (intravenous injection; 50 μg/kg or 500 μg/kg; per day) markedly decreases the sizes, weights of tumors, and YAP target genes in a dose-dependent manner in mice.
Super-TDU (intravenous injection; 250 μg/kg 500 μg/kg) has the t1/2α of 0.78 hours and 0.82 hours; the Cmax of 6.12 ng/mL and 13.3 ng/mL; the CL of 7.41 ml/min/kg and 7.72 ml/min/kg for 250 μg/kg and 500 μg/kg in mice, respectively.
Animal Model: |
BALB/cA nu/nu mice |
Dosage: |
50 μg/kg or 500 μg/kg |
Administration: |
Intravenous Injection; per day |
Result: |
Decreased the sizes, weights of tumors, and YAP target genes in a dose-dependent manner.
|
Animal Model: |
BALB/cA nu/nu mice |
Dosage: |
250 μg/kg or 500 μg/kg (Pharmacokinetic Study) |
Administration: |
Intravenous Injection |
Result: |
The t1/2α is 0.78 hours and 0.82 hours; the Cmax is 6.12 ng/mL and 13.3 ng/mL; the CL is7.41 ml/min/kg and 7.72 ml/min/kg for 250 μg/kg and 500 μg/kg in mice, respectively.
|